Brandywine Oak Private Wealth LLC Lowers Stock Position in Danaher Co. (NYSE:DHR)

Brandywine Oak Private Wealth LLC lowered its position in Danaher Co. (NYSE:DHR) by 9.7% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 1,292 shares of the conglomerate’s stock after selling 138 shares during the quarter. Brandywine Oak Private Wealth LLC’s holdings in Danaher were worth $297,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also recently added to or reduced their stakes in the company. AMF Tjanstepension AB acquired a new stake in Danaher during the 3rd quarter valued at approximately $5,923,000. Czech National Bank grew its position in shares of Danaher by 4.2% during the third quarter. Czech National Bank now owns 130,939 shares of the conglomerate’s stock worth $36,404,000 after buying an additional 5,320 shares in the last quarter. Diversified Trust Co increased its stake in shares of Danaher by 29.6% in the third quarter. Diversified Trust Co now owns 5,649 shares of the conglomerate’s stock worth $1,571,000 after buying an additional 1,289 shares during the last quarter. Miracle Mile Advisors LLC acquired a new stake in Danaher in the third quarter valued at $310,000. Finally, Mather Group LLC. boosted its stake in Danaher by 9.2% during the 3rd quarter. Mather Group LLC. now owns 8,931 shares of the conglomerate’s stock valued at $2,483,000 after acquiring an additional 749 shares during the last quarter. Hedge funds and other institutional investors own 79.05% of the company’s stock.

Insider Activity

In other news, SVP Brian W. Ellis sold 5,700 shares of Danaher stock in a transaction dated Thursday, January 30th. The stock was sold at an average price of $224.13, for a total transaction of $1,277,541.00. Following the transaction, the senior vice president now owns 20,230 shares in the company, valued at $4,534,149.90. The trade was a 21.98 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 10.90% of the stock is currently owned by corporate insiders.

Danaher Stock Performance

NYSE:DHR opened at $211.92 on Thursday. The company has a quick ratio of 1.05, a current ratio of 1.40 and a debt-to-equity ratio of 0.31. The firm has a 50-day moving average price of $234.50 and a 200 day moving average price of $252.68. The firm has a market capitalization of $153.07 billion, a PE ratio of 40.14, a price-to-earnings-growth ratio of 2.80 and a beta of 0.83. Danaher Co. has a 12-month low of $210.04 and a 12-month high of $281.70.

Danaher (NYSE:DHR) last issued its quarterly earnings data on Wednesday, January 29th. The conglomerate reported $2.14 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $2.14. Danaher had a return on equity of 10.82% and a net margin of 16.33%. During the same quarter in the previous year, the firm earned $2.09 earnings per share. Research analysts anticipate that Danaher Co. will post 7.77 earnings per share for the current fiscal year.

Danaher Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Friday, January 31st. Investors of record on Friday, December 27th were issued a dividend of $0.27 per share. The ex-dividend date was Friday, December 27th. This represents a $1.08 dividend on an annualized basis and a yield of 0.51%. Danaher’s dividend payout ratio is 20.45%.

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on DHR shares. Bank of America upgraded shares of Danaher from a “neutral” rating to a “buy” rating and set a $290.00 price objective on the stock in a research note on Friday, December 13th. Scotiabank initiated coverage on Danaher in a report on Monday, December 23rd. They issued a “sector perform” rating and a $265.00 price target on the stock. TD Cowen increased their target price on Danaher from $310.00 to $315.00 and gave the stock a “buy” rating in a research report on Wednesday, October 23rd. Citigroup lowered their price target on shares of Danaher from $285.00 to $265.00 and set a “buy” rating for the company in a research report on Thursday, January 30th. Finally, Guggenheim assumed coverage on shares of Danaher in a research report on Thursday, December 19th. They issued a “buy” rating and a $275.00 target price for the company. Seven investment analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company. According to data from MarketBeat.com, Danaher has an average rating of “Moderate Buy” and a consensus price target of $278.00.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.